Vericel (VCEL) Misses Q1 EPS by 3c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
May 5, 2021 7:00 AM EDTFirst Quarter Total Net Revenue Increased 30% to $34.6 Million
Full-Year 2021 Revenue Guidance Raised to $165-$168 Million
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2021.
First Quarter 2021 Financial Highlights
Total net revenue increased 30% to $34.6... More